

# India Glaucoma Outcomes and Treatment Trial

<b>Submission date</b> 11/10/2005	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 30/03/2006	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 11/01/2021	<b>Condition category</b> Eye Diseases	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Nathan Congdon

**Contact details**  
Wilmer 120  
600 N. Wolfe Street  
Baltimore  
United States of America  
21287  
-  
ncongdon@jhmi.edu

## Additional identifiers

**Protocol serial number**  
N/A

## Study information

**Scientific Title**  
India Glaucoma Outcomes and Treatment Trial

**Acronym**  
INGOTT

**Study objectives**

Surgery will be more effective than medicines in controlling glaucoma in India

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Approved by the Internal Review Boards at the Johns Hopkins University, Baltimore, USA and the Aravind Eye Hospital in India

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Glaucoma

**Interventions**

Medicine (timolol, latanaprost and brimonidine) versus surgery

**Intervention Type**

Procedure/Surgery

**Primary outcome(s)**

1. Intraocular pressure
2. Visual acuity
3. Quality of life

**Key secondary outcome(s))**

Cataract grade

**Completion date**

01/01/2007

**Eligibility****Key inclusion criteria**

Glaucoma patients over the age of 30 years in India

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

All

**Total final enrolment**

398

**Key exclusion criteria**

1. Previous surgery
2. Intraocular pressure (IOP) >35

**Date of first enrolment**

01/01/2003

**Date of final enrolment**

01/01/2007

**Locations****Countries of recruitment**

India

United States of America

**Study participating centre**

Wilmer 120

Baltimore

United States of America

21287

**Sponsor information****Organisation**

Pfizer Inc. (USA)

**ROR**

<https://ror.org/01xdqrp08>

**Funder(s)****Funder type**

Industry

**Funder Name**

Pfizer Inc.

## Results and Publications

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/06/2012	11/01/2021	Yes	No